AboutBIOCYTOGEN Biocytogen (SSE:688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.Biocytogen has independently developed its proprietary RenMice® (RenMab®/ RenLite®/ RenNano®/RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). About Us About the Company 2025New Office Opening Our Journey of Innovation and Growth Every step we take brings us closer to our mission: enabling breakthroughs that make a difference. Join us in shaping the future of healthcare, one innovation at a time. March Biocytogen Expands Global Reach with New San Diego Office Biocytogen (“Biocytogen,” HKEX: 02315), a global biotech company advancing antibody-based drug discovery with innovative technologies, is pleased to announce the opening of its new office in San Diego, California, reinforcing its commitment to becoming the "global headstream of new drugs." This strategic expansion will enhance global partnerships in therapeutic antibody development and preclinical solutions, leveraging advanced technologies to accelerate the development of transformative therapeutics. Read more 2023Product Launch & New Office Opening January Biocytogen Launches RenNano® Mouse Biocytogen officially launches its fully human heavy chain antibody platform, RenNano, the third member of the RenMice family. Read more May Biocytogen Opens San Francisco Office to Accelerate Globalization Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA. The new space will aim to accelerate the globalization of Biocytogen's businesses. Read more August Biocytogen Announces Grand Opening of Waltham, MA Facility Biocytogen Pharmaceuticals announced the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation. Read more 2022Expansion & HKEX Listing March Grand Opening in Germany! Announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany. September Biocytogen's Listing Ceremony Biocytogen announced the company's official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. Read more 2021New Financing & Clinical Trials June Tens of Millions in Financing Completed a new round of financing totaling tens of millions of dollars Read more June YH001 & YH003 Phase II Clinical Trials Obtained approval from the FDA to commence Phase II clinical trials for YH001 and YH003 in the U.S. Read more 2020Clinical Trials & Platform Launch January YH002 Clinical Trials Approved in U.S. Anti-OX40 antibody YH002 was approved for clinical trials in the United States March RenMice HiTS Platform Launch RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company May YH001 & YH002 Approved Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China August Biocytogen & Eucure Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide. September RenMice HiTS Platform Financing Completion of D+ round financing, enabling progression of the RenMice HiTS Platform initiative Read more 2019New Technology & Clinical Trials August RenMab Platform Launched Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July October YH001 Clinical Trials Approved in U.S. Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States 2018New Sites & Scaling Up February Biocytogen Boston Incorporated Boston and Shanghai sites opened for business April Venture Funding Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings 2016Company Expansion Haimen Animal Center Opens Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients 2015Pharmacology Platform Preclinical Services & New Funding Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund 2014Mouse Models Developed Humanized Immune-checkpoint Mice and B-NDG Mice Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model 2011Gene Editing Established Gene Editing Platform Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer. 2009Origins Beijing Biocytogen Established Beijing Biocytogen was established to commence research and development of biotechnology in China. 2008Founded in Massachusetts Founded in Massachusetts, USA Biocytogen was founded in Massachusetts in 2008 >